| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Vincent Aurentz is Director at IKT. Vincent Aurentz's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $756K at current prices.
Vincent Aurentz has 4 Form 4 filings on record from February 2025 to June 2026, all as Director at Inhibikase Therapeutics (IKT), 2025–2026.
The 4 reported transactions were 3 option or other derivative awards and 1 disposition back to the company.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria